Reducing adverse effects of immunosuppressive agents in kidney transplant recipients

Progress in Transplantation

Volumn 11, Issue 4, 2001, Pages 271-282

  Aalamian, Z ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ALOPECIA; BONE ATROPHY; COMORBIDITY; DIABETES MELLITUS; DRUG INDUCED DISEASE; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; NEPHROTOXICITY; OBESITY; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; REVIEW;

EID: 0035653018     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.1177/152692480101100409     Document Type: Review

References (107)

1. Choice of immunosuppressive drugs and individualization of immunosuppressive theraphy for kidney transplant patients
2. Immunosuppressant-induced metabolic toxicities
3. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
4. Mycophenolate mofetil-based immunosuppressive therapy: Induction, maintenance, and conversion protocols in renal transplantation
5. Strategies to reduce or replace steriod dosing
6. Transplantation in the cyclosporine and OKT3 eras: An update of the University of Wisconsin-Madison experience
7. Cardiovascular disease after renal transplantation
8. Risk for posttransplant diabetes mellitus with current immunosuppressive medications
9. Metabolic factors have a major impact on kidney allograft survival
10. Cholesterol as an independent predictor of outcome after renal transplantation
11. Arterial hypertension and renal allograft survival
12. Rapid loss of vertebral mineral density after renal transplantation
13. Factors influencing vertebral bone density after renal transplantation
14. The incidence and long-term cost of steroid related side effects after renal transplantation
15. United resource networks: How compliance issues affect a managed care transplant network
16. Patient compliance in transplantation: A report on the perceptions of transplant clinicians
17. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients
18. Nonadherence to immunosuppressive medications: A pilot survey of members of the Transplant Recipients International Organization
19. Non-compliance in renal transplant recipients with functioning grafts
20. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients
21. A randomised prospective study on the conversion from cyclosporine-prednisone to cyclosporine-azathioprine at 6 months after renal transplantation
22. Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients
23. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized study
24. Early cyclosporine monotherapy in liver transplantation: A 5-year follow up of a prospective randomized trial
25. Cardiac transplantation with corticosteroid-free immunosuppression: Long term results
26. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts
27. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression
28. A prospective, randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients
29. Withdrawal of steroids after renal transplantation: Clinical predictors of outcome
30. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
31. Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients
32. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection
33. Successful steroid withdrawal during the first year after renal transplantation in mycophenolate mofetil and cyclosporine treated patients
34. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients
35. One year outcome after steroid withdrawal from a sirolimus-cyclosporine-prednisone regimen in cadaver and living donor recipients
36. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression
37. Early corticosteroid cessation at one week following kidney transplant under tacrolimus and mycophenolate mofetil (MMF) immunosuppression, three year follow-up
38. Modified rapid steroid taper after liver transplantation with mycophenolate mofetil
39. Replacing steroids after liver transplantation
40. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy
41. Renal transplantation without steroids: A pilot study
42. Sirolimus (rapamycin)-based therapy in human renal transplantation. Similar efficacy and different toxicity compared with cyclosporine
43. Reduction of acute renal allograft rejection by daclizumab
44. Renal transplantation without steroids - One year results of a multicentre Canadian pilot study
45. The adverse impact of cyclosporine on serum lipids in renal transplant recipients
46. Impact of longterm immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients
47. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine
48. Effects of tacrolimus on hyperlipidemia after successful renal transplantation
49. Altered flow properties of blood and increased plasma fibrinogen in cyclosporine-treated renal allograft recipients
50. Fibrinogen and risk of vascular disease: The Framingham study
51. Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients
52. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production in healthy humans
53. Cyclosporine in therapeutic doses increases allograft vascular resistance
54. Immunosuppressant-induced nephropathy
55. Cyclosporine-induced renal dysfunction in experimental animals and humans
56. Functional and structural characteristics of experimental FK 506 nephrotoxicity
57. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK506
58. A comparison of tacrolimus (FK506), and cyclosporine for immunosuppression in liver transplantation
59. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
60. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience
61. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
62. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling
63. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation
64. Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats
65. Association of chronic kidney graft failure with recipient blood pressure. Collaborative transplant study
66. Long-term efficacy and safety of cyclosporine in renal transplant recipients
67. Long-term maintenance of therapeutic cyclosporine levels leads to optimal graft survival without evidence-of chronic nephrotoxicity
68. Long-term renal function in heart transplant recipients receiving cyclosporine therapy
69. Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Incidence and progression
70. Cyclosporine nephrotoxicity in lung transplant recipients
71. The long-term course of cyclosporine-associated chronic nephropathy
72. Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant recipients
73. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine
74. Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients
75. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation
76. Chronic cyclosporine nephrotoxicity
77. The differential diagnosis between rejection and cyclosporine toxicity
78. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group
79. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation
80. Fibrous hyperplasia of the gingiva: A side effect of cyclosporin A therapy
81. Elective cyclosporine withdrawal after renal transplantation
82. Who should be converted from cyclosporine to conventional immmunosuppression in kidney transplantation, and why
83. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation
84. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation
85. Randomized prospective trial of elective cyclosporine withdrawal from triple therapy at 6 months after cadaveric renal transplantation
86. Elective cyclosporine withdrawal in renal transplant recipients maintained on triple therapy
87. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function
88. Chronic allograft nephropathy: Effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease
89. The long-term impact of calcineurin inhibitor reduction or discontinuation in patients with declining kidney function due to chronic allograft nephropathy
90. Preliminary results of a randomised, controlled study investigating the withdrawal of neoral in stable renal transplant recipients receiving mycophenolate mofetil in addition to neoral and steroids
91. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associate nephrotoxicity
92. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients
93. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation?
94. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil
95. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporineinduced renal impairment. A preliminary report
96. Improvement of renal dysfunction secondary to cyclosporine in long-term liver transplant patients receiving mycophenolate mofetil and very low-dose neoral
97. Complete conversion of immunosuppression from cyclosporine to mycophenolate mofetil in patients with renal insufficiency following HTX
98. Benefit of mycophenolate-mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation
99. Can antibody prophylaxis allow sparing of other immunosuppressives?
100. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial
101. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation
102. In vivo expression of transfrming growth factor-b1 in humans
103. Sustained expresion of TGF-b1 underlies development of progressive kidney fibrosis
104. Transfrming growth factor (TGF)-b mimics and anti-TGF-b antiboy abrogates the in vivo effects of cyclosporine: Demonsration of a direct role of TGF-b in immunosuppression ad nephrotoxicity of cyclosporine
105. Decreasing expression of transforming growth factor beta in human renal biopsies with improvment of renal pathological score and renal function followng chronic cyclosporine reduction
106. Nonnephrotoxic, nonatherogenic maintenance therapy in kidney-transplanted patients using MMF mootherapy: A pilot study